published meta-analysis   sensitivity analysis   studies

favipiravir plus interferon in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsKhamis, 2020 0.83 [0.23; 2.96] 0.83[0.23; 2.96]Khamis, 202010%89NAnot evaluable ICU admissiondetailed resultsKhamis, 2020 1.03 [0.35; 3.03] 1.03[0.35; 3.03]Khamis, 202010%89NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:22 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 884 - roots T: 290